MedWatch

Novo-researcher turned PhD project into company and prepares for phase II

Sweden-based biotech firm Pila Pharma is about to initiate a phase II study with a brand new form of type 2 diabetes treatment. What started as a PhD project in Novo Nordisk's laboratories is now to be transformed into a cost-effective therapy that can compete with other classes of diabetes drugs.

Foto: Pila Pharma/PR

At the turn of the millennium, Dorte Gram often visited Novo Nordisk as a PhD student from university of Copenhagen, and until 2009 she worked as a researcher for the Danish drug group.

She was involved in various projects such as the development of the insulin drug Tresiba and Novo's newest growth asset, the GLP-1 analog semaglutide, but she never completely let go of her PhD project focusing on the use of receptors for the active substance in chili as treatment against type 2 diabetes.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier